^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Qibeian (iparomlimab/tuvonralimab)

    i
    Other names: PSB205 , PSB-205, PSB 205 , Anti-PD-1/CTLA-4 MabPair, QL1706, PBS-103/PBS-105, QL 1706, QL-1706
    Company:
    Qilu Pharma, Sound Biologics
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor
    Related drugs:
    3d
    SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=89, Not yet recruiting, Fujian Cancer Hospital
    New P2 trial
    |
    Jiataile (sacituzumab tirumotecan) • Qibeian (iparomlimab/tuvonralimab)
    3d
    QLC5508-201: A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=444, Recruiting, Qilu Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    cisplatin • carboplatin • paclitaxel • 5-fluorouracil • oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • MHB088C
    3d
    QLMA-IIT-CC-001: Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC (clinicaltrials.gov)
    P2, N=30, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • Qibeian (iparomlimab/tuvonralimab)
    10d
    Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer (clinicaltrials.gov)
    P2, N=188, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    carboplatin • docetaxel • Perjeta (pertuzumab) • Qibeian (iparomlimab/tuvonralimab)
    10d
    A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC (clinicaltrials.gov)
    P1, N=30, Recruiting, Xijing Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    carboplatin • albumin-bound paclitaxel • cyclophosphamide • Qibeian (iparomlimab/tuvonralimab) • Pinorubin (pirarubicin)
    15d
    QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=45, Recruiting, Sun Yat-sen University | Initiation date: Jun 2025 --> Sep 2025
    Trial initiation date
    |
    Qibeian (iparomlimab/tuvonralimab)
    16d
    Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    cisplatin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    16d
    DUBHE-L-303: A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=606, Active, not recruiting, Qilu Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • Qibeian (iparomlimab/tuvonralimab) • BGB-108
    17d
    A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment (clinicaltrials.gov)
    P2, N=18, Not yet recruiting, Harbin Medical University
    New P2 trial • pMMR
    |
    Fruzaqla (fruquintinib) • Qibeian (iparomlimab/tuvonralimab)
    17d
    A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Chemotherapy (FOLFOXIRI) as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Yanqiao Zhang
    New P2 trial • pMMR
    |
    BRAF (B-raf proto-oncogene)
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium • Qibeian (iparomlimab/tuvonralimab)
    1m
    An exploratory study on tuvonralimab/iparomlimab combined with chemotherapy for the treatment of advanced non-small cell lung cancer patients with EGFR uncommon mutations (ChiCTR2500111278)
    P=N/A, N=20, Not yet recruiting, Cancer Hospital, Chinese academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences
    New trial
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    A Prospective, Multicenter, Dual-Cohort Study Exploring the Efficacy and Safety of QL1706 Plus Lenvatinib With or Without Cyclophosphamide in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (ChiCTR2500110660)
    P2, N=50, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial
    |
    Lenvima (lenvatinib) • cyclophosphamide • Qibeian (iparomlimab/tuvonralimab)